News and reporting on lung cancer.
Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.
Funds raised will help accelerate commercialization of the firm's InVisionFirst-Lung liquid biopsy test and support development of the firm's platform for new indications
The partners will develop patient-specific assays based on ArcherDx's anchored multiplex PCR technology to track disease recurrence in lung cancer patients.
With RNA sequencing and other data, researchers gauged neoantigen formation, immunoediting, and clonal evolution in non-small cell lung cancers.
The firm said revenues from its precision oncology business increased 98 percent in Q4, driven by higher testing volume and increased revenue per test.
Analyzing mutational signatures in cancer cell lines and xenografts, investigators identified mutagenic processes that do or don't remain active in vitro.
Researchers at RMIT University have described collecting bronchial brushings as part of a molecular approach that may enable diagnosing lung cancer patients and guiding therapies.
The firm will expand on its MSI assay for use in immunotherapy while developing liquid biopsy assays to monitor patients post therapy and for recurrence.
The ctDNA test will be covered for all US fee-for-service Medicare patients with advanced (Stage IIIB/IV) NSCLC who meet specific clinical criteria.
The index — which outperformed the Dow Jones, the Nasdaq, and the Biotechnology Index this month — gained more than 8 percent.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.